These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 30075534

  • 1. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
    Lomonte ABV, Radominski SC, Marcolino FMD, Brenol CV, Zerbini CAF, García EG, Akylbekova EL, Rojo R, de Leon DP.
    Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
    [Abstract] [Full Text] [Related]

  • 2. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S.
    Arthritis Res Ther; 2016 Jan 28; 18():34. PubMed ID: 26818974
    [Abstract] [Full Text] [Related]

  • 3. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
    Li Z, An Y, Su H, Li X, Xu J, Zheng Y, Li G, Kwok K, Wang L, Wu Q.
    Int J Rheum Dis; 2018 Feb 28; 21(2):402-414. PubMed ID: 29314645
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS, ORAL Strategy investigators.
    Lancet; 2017 Jul 29; 390(10093):457-468. PubMed ID: 28629665
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
    Bird P, Bensen W, El-Zorkany B, Kaine J, Manapat-Reyes BH, Pascual-Ramos V, Witcombe D, Soma K, Zhang R, Thirunavukkarasu K.
    J Clin Rheumatol; 2019 Apr 29; 25(3):115-126. PubMed ID: 29794874
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
    Burgos-Vargas R, Cardiel M, Xibillé D, Pacheco-Tena C, Pascual-Ramos V, Abud-Mendoza C, Mahgoub E, Rahman M, Fan H, Rojo R, García E, Santana K.
    Reumatol Clin (Engl Ed); 2019 Apr 29; 15(1):43-53. PubMed ID: 28552437
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
    Chopra A, Shobha V, Chandrashekara S, Veeravalli SCM, Sharma R, Rao UR, Pandya S, Wagh S, Kadel JK, Thorat AV, Adhav C, Santos Estrella P, Yu W, Kwok K, Wouters A.
    Int J Rheum Dis; 2020 Jul 29; 23(7):882-897. PubMed ID: 32478474
    [Abstract] [Full Text] [Related]

  • 19. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
    van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, ORAL Scan Investigators.
    Arthritis Rheum; 2013 Mar 29; 65(3):559-70. PubMed ID: 23348607
    [Abstract] [Full Text] [Related]

  • 20. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
    Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R.
    Semin Arthritis Rheum; 2018 Dec 29; 48(3):406-415. PubMed ID: 30177460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.